GlassScriptPhysician profile
Michael J Mcmullen
NPI 1235450628
$3,686.00
in general payments reported to CMS, 2019-2025
25 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $195 · 2021: $624 · 2022: $541 · 2023: $687 · 2024: $629 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $715.43 | 2021-2025 | Clareon, Argos, Hydrus Microstent |
| Abbvie INC. | $667.60 | 2022-2025 | |
| Allergan, INC. | $350.70 | 2019-2022 | |
| New World Medical,INC. | $326.38 | 2022-2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Biotissue Holdings INC. | $261.05 | 2025 | |
| Janssen Pharmaceuticals, INC | $218.24 | 2021-2022 | |
| Horizon Therapeutics Plc | $184.38 | 2020-2023 | Tepezza |
| Glaukos Corporation | $165.23 | 2022-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite, Idosetr |
| Aerie Pharmaceuticals, INC. | $143.10 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $130.22 | 2022-2025 | Miebo, Scoutpro Osmolarity System, Vyzulta |
| Oyster Point Pharma, INC. | $84.93 | 2022-2025 | Ryzumvi, Tyrvaya |
| Mallinckrodt Hospital Products INC. | $76.36 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53.01 | 2021 | |
| Thea Pharma INC. | $47.71 | 2023 | Iyuzeh |
| Mallinckrodt Enterprises LLC | $40.79 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $34.00 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Amgen INC. | $33.91 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $27.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.94 | 2019 | |
| Sight Sciences, INC. | $22.85 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Shire North American Group INC | $18.22 | 2019 | |
| Apellis Pharmaceuticals, INC. | $16.17 | 2025 | Syfovre |
| Ocular Therapeutix, INC. | $15.41 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $15.30 | 2024 | Iolmaster 700 |
| Johnson & Johnson Surgical Vision, INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcmullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.